The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) monotherapy vs standard-of-care for ER+, HER2- advanced or metastatic breast cancer patients after endocrine therapy and CDK4/6 inhibitors.
 
Barbara Pistilli
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/UCB Japan; Myriad Genetics; Novartis; Olema Oncology (Inst); PIERRE FABRE; Puma Biotechnology
Research Funding - AstraZeneca (Inst); DAIICHI-SANKYO (Inst); Gilead Sciences (Inst); Merus (Inst); Pfizer (Inst); Puma Biotechnology (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo Europe GmbH; MSD Oncology; Novartis; Pfizer; Pierre Fabre
 
Joohyuk Sohn
Stock and Other Ownership Interests - Daiichi Sankyo (I)
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol Myerss guibb (Inst); Celcuity (Inst); Daiichi Sankyo (Inst); Dragonfly Therapeutics (Inst); Eikon (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hanmi Pharm (Inst); HLB Life Science (Inst); ILDONG PHARMACEUTICAL (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Olema Oncology (Inst); Pfizer (Inst); Qurient (Inst); Roche (Inst); Samyang Holdings (Inst); Sanofi (Inst); Seagan (Inst); Sermonix Pharmaceuticals (Inst)
 
Peter Schmid
Employment - Roche (I)
Honoraria - AstraZeneca; Bayer; Bayer; Boehringer Ingelheim; Celgene; Celgene; Eisai; Genentech (Inst); Gilead Sciences Hong Kong; Merck; Novartis; Oncogenex (Inst); Oncogenex (Inst); Pfizer; Puma Biotechnology; Roche; Sanofi; Stemline Therapeutics
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Genentech/Roche (I); Merck; Novartis; Pfizer; Puma Biotechnology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Medivation; Novartis (Inst); Oncogenex (Inst); Roche (Inst)
Travel, Accommodations, Expenses - ESMO; SABS
 
Meritxell Bellet
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Stemline Menarini
Speakers' Bureau - Lilly; Novartis; Pfizer
Travel, Accommodations, Expenses - Novartis; Pfizer; Roche
 
Lucia Del Mastro
Honoraria - Gilead Sciences; Lilly; MSD Oncology; Novartis; Roche
Consulting or Advisory Role - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Exact Sciences; Gilead Sciences; GlaxoSmithKline; Ipsen; Lilly; Menarini; MSD; Novartis; Olema Oncology; Pfizer; Pierre Fabre; Roche; Seagen
Research Funding - AstraZeneca (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Olema Oncology; Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Pfizer; Roche
 
Jane Meisel
Consulting or Advisory Role - AstraZeneca; GE Healthcare; Genentech; Novartis; Olema Oncology; Pfizer; SeaGen; Sermonix Pharmaceuticals; Stemline Therapeutics
Research Funding - AstraZeneca (Inst); Olema Oncology (Inst); Pfizer (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst)
 
Arlene Chan
Honoraria - Eisai; Lilly
Travel, Accommodations, Expenses - Olema Oncology
 
Elisabeth de Kermadec
Employment - Olema Oncology
 
Lianqing Zheng
Employment - Kite, a Gilead Company; Olema Oncology
 
Heather McArthur
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Lilly; Merck; Moderna Therapeutics; Novartis; Pfizer
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)